Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients

Amikacin is commonly used for probabilistic antimicrobial therapy in critically ill patients with sepsis. Its narrow therapeutic margin makes it challenging to determine the right individual dose that ensures the highest efficacy target attainment rate (TAR) in this setting. This study aims to devel...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Main Authors: Boidin, Clément, Bourguignon, Laurent, Cohen, Sabine, Roger, Claire, Lefrant, Jean-Yves, Roberts, Jason A., Allaouchiche, Bernard, Lepape, Alain, Friggeri, Arnaud, Goutelle, Sylvain
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2019
Assuntos:
Pharmacology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6811403/
https://ncbi.nlm.nih.gov/pubmed/31481443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00993-19
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares